Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 75

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 75
---
 be paid for in cash or by exchange of securities or other assets); (3) where no consideration is or will be given for the transfer; (4) where the transfer is by operation of law; (5) as specified in Section 276(7) of the SFA; or (6) as specified in Regulation 32.

Singapore Securities and Futures Act Product Classification — Solely for the purposes of its obligations pursuant to Sections 309B(1)(a) and 309B(1)(c) of the SFA, the Issuer has determined, and hereby notifies all relevant persons (as defined in Section 309A of the SFA) that the notes are “prescribed capital markets products” (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018).

#### Switzerland
This prospectus is not intended to constitute an offer or solicitation to purchase or invest in the notes described herein. The notes may not be publicly offered, sold or advertised, directly or indirectly, in or into Switzerland within the meaning of the Swiss Financial Services Act (“FinSA”), except (i) to any investor that qualifies as a professional or institutional client within the meaning of Article 4(3) and Article 4(4) of the FinSA, (ii) to any investor that acquires the notes in the context of a portfolio management agreement with

<div align='center'>S-40</div>

TABLE OF CONTENTS

a licensed Swiss financial institution, or (iii) under any other applicable exemption under the FinSA, and further provided that no such offer of notes shall require the publication of a prospectus and/or the publication of a key information document (or an equivalent document) pursuant to the FinSA, and/or a registration or authorization of AMS Europe, Boston Scientific and the notes in Switzerland. The notes have not and will not be listed or admitted to trading on any trading venue in Switzerland.

Neither this prospectus nor any other offering or marketing material relating to the notes, AMS Europe or Boston Scientific constitutes a prospectus or a key information document (or an equivalent document) as such terms are understood pursuant to the FinSA, and neither this prospectus nor any other offering or marketing material relating to the notes, AMS Europe or Boston Scientific may be distributed or otherwise made available in Switzerland in a manner which would require the publication of a prospectus or a key information document (or an equivalent document) in Switzerland pursuant to the FinSA, and/or a registration or authorization of AMS Europe,